GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 54 [PMID: 34374541]
Compound class:
Synthetic organic
Comment: HSK31858 (Haisco, Chiesi) is an irreversible, oral dipeptidyl peptidase-1 inhibitor (DPP-1; cathepsin C) inhibitor [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chen X, Yan Y, Zhang Z, Zhang F, Liu M, Du L, Zhang H, Shen X, Zhao D, Shi JB et al.. (2021)
Discovery and In Vivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor. J Med Chem, 64 (16): 11857-11885. [PMID:34374541] |
2. Wang Y, Yu C, Hu M, Wang L, Chen M, Liu H, Wu N, Hou J. (2025)
Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase-1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Br J Clin Pharmacol, [Epub ahead of print]. [PMID:40170587] |
3. Zhong NS, Qiu R, Cao J, Huang YM, Zhou H, Xu XX, Xu JF, Ye H, Yang ZR, Gao LY et al.. (2025)
Effects of the DPP-1 inhibitor HSK31858 in adults with bronchiectasis in China (SAVE-BE): a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Respir Med, 13 (5): 414-424. [PMID:40154523] |